Lupin Launches Liraglutide Injection in the U.S. Market

Mumbai, October 3, 2025 – Lupin Limited has announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen, in the United States. The product is the generic equivalent of Victoza® Injection by Novo Nordisk Inc., and is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. According to IQVIA data, the reference drug Victoza® reported annual U.S. sales of approximately USD 350 million as of August 2025. Commenting on the launch, Spiro Gavaris, President – U.S. Generics at Lupin, highlighted that the addition of Liraglutide significantly strengthens Lupin’s complex injectables portfolio and demonstrates the company’s commitment to expanding patient access to essential therapies. Lupin, headquartered in Mumbai, India, is a global pharmaceutical leader with a presence in more than 100 markets. Its portfolio covers branded and generic formulations, complex generics, biotechnology products, and APIs, across therapy areas such as respiratory, cardiovascular, diabetes, CNS, gastrointestinal, women’s health, and anti-infectives. The company operates 15 manufacturing facilities and 7 R&D centers worldwide, supported by over 24,000 employees. This disclosure was made under SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015 and communicated to both the National Stock Exchange of India (NSE) and BSE Limited. For queries, Lupin has provided contact details of Rajalakshmi Azariah, Vice President & Global Head – Corporate Communications. ✅ Disclaimer: This article is for informational purposes only and should not be considered investment advice. 👉 Follow me for more corporate and market updates.